Slide 1: Q2 2022 webcast
1 Q2 2022 webcast CEO Pär Fors CFO Pernille Fabricius 12 August, 2022 1
Slide 2: Agenda
Agenda • Q2 highlights • Strategic update • Business Unit performance • Group financials • 2022 outlook • Q&A Disclaimer This presentation contains forward-looking statements including projections on future financial results. Statements regarding the future are subject to risks and uncertainties tha
Slide 3: Q2 highlights
Q2 highlights • Transformative divestment of Revenue and operating margin infrastructure business announced 1000 5.1% 5.1% 10 2.9% -1.3% 500 0 • Consolidation of global delivery 710 698 738 701 723 -1.5% capabilities on track 0 -10 Q2-21 Q3-21 Q4-21 Q1-22 Q2-22 Revenue (DKKm) Operating profit margin
Slide 4: Strategic update
Strategic update TRANSFORMATION PROFITABILITY STRATEGY Divestment sharpens focus Continued cost reductions Increase growth and profitability as specialized IT services including consolidation of Two core business units provider in growth areas global delivery capabilities Continued focus on M&A NEXT
Slide 5: Life Sciences Solutions (LSS)
Life Sciences Solutions (LSS) • 33% growth mainly driven by Revenue and gross margin acquisitions 300 24.8% 24.0% 24.9% 19.1% 30 14.0% 200 10 • Cancelled project continued to 100 166 191 199 198 222 impact organic growth and margins 0 -10 Q2-21 Q3-21 Q4-21 Q1-22 Q2-22 Revenue (DKKm) Gross margin (%)
Slide 6: Cloud & Digital Solutions (CDS)
Cloud & Digital Solutions (CDS) • Revenue and margins impacted by Revenue and gross margin lower utilization and higher costs 300 14.5% 12.4% 18.3% 12.6% 9.1% 20 200 10 • Lower Public customer sales and 100 213 199 225 213 206 0 impact of postponed ERP project 0 -10 Q2-21 Q3-21 Q4-21 Q1-22 Q2-22 Rev
Slide 7: Hybrid Cloud Solutions (HCS)
Hybrid Cloud Solutions (HCS) • Continued impact of renegotiated Revenue and gross margin NNG infrastructure agreement 400 9.9% 5.9% 20 4.7% 3.4% 2.5% 10 200 • Measures intiated to increase 331 308 314 290 295 0 capacity utilization 0 -10 Q2-21 Q3-21 Q4-21 Q1-22 Q2-22 Revenue (DKKm) Gross margin (%)
Slide 8: Group financials Q2 and 6M 2022
Group financials Q2 and 6M 2022 Q2-22 BU revenue DKKm Q2-22 Q2-21 6M-22 6M-21 FY-21 Revenue 723 710 1,424 1,441 2,877 Revenue growth 1.8% 1.3% -1.2% 1.3% 1.7% 31% 41% Gross profit 66 105 132 225 420 Sales and marketing costs 40 35 78 73 145 28% Administrative expenses 37 34 74 68 133 Operating profi
Slide 9: 2022 outlook suspended
2022 outlook suspended • IO business to be reclassified as ‘discontinued activities’ • Impact on financial reporting is being settled • Temporary suspension maintained • 2022 guidance to be introduced in H2 • Strengthen revenue and profitability of continuing activities from 2023 9
Slide 10: Closing remarks
Closing remarks Significant strategic Continued order backlog Settling impact of moves initiated and growth with wins across divestment on progressed in Q2 Business Units continuing business 10
Slide 11: Q&A
Q&A NNIT
Slide 12: Contact information
Contact information Pernille Fabricius CFO PNFA@nnit.com Financial calendar 2022 Interim report Q3 November 2, 2022 12
Slide 13: We make a mark
We make a mark nnit.com ANIT
Slide 14: Appendix: Life Sciences Solutions
Appendix: Life Sciences Solutions DKKm Q2 2022 Q1 2022 Q4 2021 Q3 2021 Q2 2021 Revenue 222 198 199 191 166 Life Sciences (excl. NGG) 201 170 175 166 145 - Life Sciences (Int.) 192 163 167 160 137 - Life Sciences (DK) 9 7 8 6 8 Novo Nordisk Group 21 28 24 24 20 Public 0 0 0 1 1 Production costs 180 1
Slide 15: Appendix: Cloud & Digital Solutions
Appendix: Cloud & Digital Solutions DKKm Q2 2022 Q1 2022 Q4 2021 Q3 2021 Q2 2021 Revenue 206 213 225 199 213 Life Sciences (excl. NGG) 36 35 40 31 35 - Life Sciences (Int.) 12 11 17 12 16 - Life Sciences (DK) 23 24 23 19 19 Novo Nordisk Group 23 23 23 21 22 Enterprise 103 106 111 101 101 Public 37 4
Slide 16: Appendix: Hybrid Cloud Solutions
Appendix: Hybrid Cloud Solutions DKKm Q2 2022 Q1 2022 Q4 2021 Q3 2021 Q2 2021 Revenue 295 290 314 308 331 Life Sciences (excl. NGG) 37 39 45 48 53 - Life Sciences (Int.) 10 14 15 15 12 - Life Sciences (DK) 27 25 30 33 41 Novo Nordisk Group 90 89 107 98 108 Enterprise 86 81 83 81 85 Public 22 24 25 2